26.11.2019
- US Merck & Co. has agreed to buy Calporta Therapeutics for up to $576 million, including an upfront sum and contingent milestone payments. Calporta was launched in early 2015 by...
15.11.2019
- US Merck & Co. is eliminating 200 manufacturing and R&D jobs in France as part of a $1.2 billion worldwide restructuring of operations. The axe will fall on 101 production and 106...
31.05.2019
- A recent decision by the US Supreme Court to remand a number of product liability lawsuits against US drugmaker Merck & Co to an appeals court has peaked the pharmaceutical...
02.05.2019
- US drugmaker Merck & Co. has begun a restructuring program of its manufacturing and supply network, as well as reducing its global real estate footprint. The disclosure was made in...
12.09.2018
- Italian research organization IRBM has signed a new agreement with Merck & Co on peptides therapeutics, extending a collaboration begun in 2010. In the newest round, it will...
18.06.2018
- The US Food and Drug Administration (FDA) has granted two more approvals for US Merck’s Keytruda, an anti-PD-1 therapy. In the first, the drug gained its first regulatory clearance...
22.02.2018
- US drugmakerMerck & Co. has agreed to buy Australia’s Viralytics for $394 million, in a deal that will boost its immuno-oncology portfolio. Through the acquisition, which will see...
16.02.2018
- US drugmaker Merck & Co. has said it will halt its APECS randomized, placebo-controlled, parallel-group, double-blind Phase 3 clinical trial evaluating the efficacy and safety of...
